Products

Etaracizumab (TAB-025)

Recombinant monoclonal antibody to Human CD51+CD61. Etaracizumab (also known as etaratuzumab, MEDI-522, trade name Abegrin) is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer, ovarian cancer and various other types of cancer.      

  • Published Data
  • Datasheet
FC

Figure 1 Expression of αvβ3 in ovarian cancer cell lines.

Recognition of the αvβ3 heterodimer was assessed first by flow cytometry, using the murine monoclonal antibody clone LM609 as primary antibody (A). This is the clone from which the etaracizumab antibody was derived and shares identical Fab′ regions. There is a high expression of αvβ3 in the SKOV3ip1 and HeyA8 lines, and expression in a smaller population in A2780ip2. LM609 does not bind to αvβ3 in murine endothelial cells. Modified immunoprecipitation was then performed, where cells were exposed to biotin in culture, immunoprecipitated with anti-αv, anti-β3, or control IgG, then separated by SDS-PAGE electrophoresis (B). Bands at the expected location of the αv and β3 integrin subunits (125 and 105 kDa, respectively) are noted when either primary antibody was used in SKOV3ip1 and HeyA8. Expression in A2780ip2 was not high enough to be detected by this method.

Landen, C. N., Kim, T. J., Lin, Y. G., Merritt, W. M., Kamat, A. A., Han, L. Y.,... & Tice, D. (2008). Tumor-selective response to antibody-mediated targeting of αvβ3 integrin in ovarian cancer. Neoplasia, 10(11), 1259-1267.

WB

Figure 2 Effects of etaracizumab on the AKT pathway.

To explore an explanation for the differential effects seen in vivo in SKOV3ip1 and HeyA8 despite αvβ3 expression, we examined effects of exposure to etaracizumab on cells plated on vitronectin. Cell lysate from cells exposed for 24 hours was collected and tested for phosphorylated Akt (p-Akt), total Akt2 (tot Akt2), total Akt1 (tot
Akt1), phosphorylated PI3 kinase 85-kDa subunit (p-PI3K-85), phosphorylated PI3 kinase 55-kDa subunit (p-PI3K-55), phosphorylated mTOR (p-mTOR), and β-actin (A). Band intensity was quantified with Scion Image and normalized with β-actin band intensity, and the change noted with etaracizumab is shown (B). At 24 hours in the SKOV3ip1 cell line, phosphorylated Akt, total Akt1, and total Akt2 were all decreased with treatment, as was phosphorylated mTOR. Interestingly, phosphorylated PI3K–55-kDa subunit was increased with treatment. No treatment effect was seen in HeyA8 at 24 hours, although the pathway was shown to be intact by higher phosphorylated Akt (in both treatment groups) at 5 minutes, likely a transient effect due to a change to low-serum media. Phosphorylated mTOR was not measurable (NM) in HeyA8 at 5 minutes and
24 hours.

Landen, C. N., Kim, T. J., Lin, Y. G., Merritt, W. M., Kamat, A. A., Han, L. Y.,... & Tice, D. (2008). Tumor-selective response to antibody-mediated targeting of αvβ3 integrin in ovarian cancer. Neoplasia, 10(11), 1259-1267.

Inhib

Figure 3 Mechanisms of etaracizumab effects on ovarian cancer.

In an MTT viability assay, cells were allowed to grow on uncoated wells or wells precoated with vitronectin, with increasing concentrations of etaracizumab (A). At low concentrations of etaracizumab, vitronectin promoted cell viability. However, at higher concentrations of etaracizumab, viability was inhibited on cells grown on vitronectin,
the αvβ3 receptor. Etaracizumab did not affect viability when wells were not precoated with vitronectin. Data shown is in SKOV3ip1, with HeyA8 giving similar results. To assess in vivo effects on tumor biology, tumors were collected at the conclusion of the therapy experiments described in Figure 2 and tested for proliferation index as determined by PCNA positivity (B) and microvessel density as determined by number of CD31-positive lumens (C). The mean number of PCNA-positive cells or vessels in five randomly selected fields were counted and compared between groups. Consistent with in vitro proliferation data, etaracizumab (eta) reduced the proliferation index compared to IgG-exposed tumors, though there was no significant difference between IgG/paclitaxel– (IgG + pac) and etaracizumab/paclitaxel– (eta + pac) treated tumors. However, all four groups were similar in microvessel density, which may be a reflection of the lack of recognition of the murine αvβ3 integrin by etaracizumab. Finally, using the MICS, cell invasion through a human defined matrix in SKOV3ip1 and HeyA8 were examined with and without etaracizumab (D). Blockade of αvβ3 leads to a dose-dependent inhibition of invasion in both cell lines.

Landen, C. N., Kim, T. J., Lin, Y. G., Merritt, W. M., Kamat, A. A., Han, L. Y.,... & Tice, D. (2008). Tumor-selective response to antibody-mediated targeting of αvβ3 integrin in ovarian cancer. Neoplasia, 10(11), 1259-1267.


Specifications
Immunogen
The details of the immunogen for this antibody are not available.
Host
Mouse
Derivation
Humanized (from mouse)
Type
IgG1
Specificity
Tested positive against native human antigen
Species Reactivity
Human
Applications
IP, IF, FuncS, FC, Neut, ELISA, ICC, WB, Inhib
Trade name
abegrin
CAS NO.
892553-42-3
Generic Name
Etaracizumab
UNII
41W9MFI160
M.W.
144.3 kDa
Related Disease
Melanoma, metastatic
Applications
Application Notes
The ITGAV+ITGB3 antibody has been reported in applications of IP, IF, FuncS, FC, Neut, ELISA, ICC, WB, Inhib.
Target
Alternative Names
Etaracizumab; abegrin; 892553-42-3; MEDI-522; hLM609; Vitaxin; LM609; etaratuzumab

For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Send Inquiry Now!
Name:
* Phone:
* E-mail Address:
* Service & Products Interested:
Project Description:
* Verification Code:
Verification code
Click image to refresh the verification code.

Contact Us to Order
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Increase Efficiency to Accelerate Your Research & Discovery Process

Increase Efficiency to Accelerate Your Research & 
Discovery Process

Creative Biolabs is the leading custom service provider that has extensive experience in various antibody production and engineering fields. Our service portfolio includes mouse and rat monoclonal antibody production ...

Find out more >

USA

45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356

Europe

Tel: 44-207-097-1828
Email:
Follow us on:
        

Terms of Service-Privacy Policy     © 2007 - 2019 Creative-Biolabs All Rights Reserved